Literature DB >> 25917683

COGNITION-CHILDHOOD MALTREATMENT INTERACTIONS IN THE PREDICTION OF ANTIDEPRESSANT OUTCOMES IN MAJOR DEPRESSIVE DISORDER PATIENTS: RESULTS FROM THE iSPOT-D TRIAL.

Shefali Miller1,2, Lisa M McTeague1,2, Anett Gyurak1,2,3, Brian Patenaude1,2, Leanne M Williams1,2, Stuart M Grieve4,5,6, Mayuresh S Korgaonkar4,7, Amit Etkin1,2.   

Abstract

BACKGROUND: Childhood maltreatment (CM) history has been associated with poor treatment response in major depressive disorder (MDD), but the mechanisms underlying this relationship remain opaque. Dysfunction in the neural circuits for executive cognition is a putative neurobiological consequence of CM that may contribute importantly to adverse clinical outcomes. We used behavioral and neuroimaging measures of executive functioning to assess their contribution to the relationship between CM and antidepressant response in MDD patients.
METHODS: Ninety eight medication-free MDD outpatients participating in the International Study to Predict Optimized Treatment in Depression were assessed at baseline on behavioral neurocognitive measures and functional magnetic resonance imaging during tasks probing working memory (continuous performance task, CPT) and inhibition (Go/No-go). Seventy seven patients completed 8 weeks of antidepressant treatment. Baseline behavioral and neuroimaging measures were assessed in relation to CM (history of childhood physical, sexual, and/or emotional abuse) and posttreatment depression outcomes.
RESULTS: Patients with maltreatment exhibited decreased modulation of right dorsolateral prefrontal cortex (DLPFC) activity during working memory updating on the CPT, and a corresponding impairment in CPT behavioral performance outside the scanner. No between-group differences were found for imaging or behavior on the Go/No-go test of inhibition. Greater DLPFC activity during CPT significantly predicted posttreatment symptom improvement in patients without maltreatment, whereas the relationship between DLPFC activity and symptom change was nonsignificant, and in the opposite direction, in patients with maltreatment.
CONCLUSIONS: The effect of CM on prefrontal circuitry involved in executive function is a potential predictor of antidepressant outcomes.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  depression; executive function; neuroimaging; prefrontal cortex; stress; treatment outcome

Mesh:

Substances:

Year:  2015        PMID: 25917683      PMCID: PMC4841677          DOI: 10.1002/da.22368

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  52 in total

1.  Reduced hippocampal activity in youth with posttraumatic stress symptoms: an FMRI study.

Authors:  Victor G Carrión; Brian W Haas; Amy Garrett; Suzan Song; Allan L Reiss
Journal:  J Pediatr Psychol       Date:  2009-12-07

2.  Early-life stress is associated with impairment in cognitive control in adolescence: an fMRI study.

Authors:  Sven C Mueller; Francoise S Maheu; Mary Dozier; Elizabeth Peloso; Darcy Mandell; Ellen Leibenluft; Daniel S Pine; Monique Ernst
Journal:  Neuropsychologia       Date:  2010-06-16       Impact factor: 3.139

Review 3.  Neurobiological and psychiatric consequences of child abuse and neglect.

Authors:  Christine Heim; Margaret Shugart; W Edward Craighead; Charles B Nemeroff
Journal:  Dev Psychobiol       Date:  2010-11       Impact factor: 3.038

4.  Impact of the HTR3A gene with early life trauma on emotional brain networks and depressed mood.

Authors:  Justine M Gatt; Leanne M Williams; Peter R Schofield; Carol Dobson-Stone; Robert H Paul; Stuart M Grieve; C Richard Clark; Evian Gordon; Charles B Nemeroff
Journal:  Depress Anxiety       Date:  2010-08       Impact factor: 6.505

5.  Accurate and robust brain image alignment using boundary-based registration.

Authors:  Douglas N Greve; Bruce Fischl
Journal:  Neuroimage       Date:  2009-06-30       Impact factor: 6.556

6.  Posttraumatic stress symptoms and brain function during a response-inhibition task: an fMRI study in youth.

Authors:  Victor G Carrion; Amy Garrett; Vinod Menon; Carl F Weems; Allan L Reiss
Journal:  Depress Anxiety       Date:  2008       Impact factor: 6.505

Review 7.  The neural circuitry of executive functions in healthy subjects and Parkinson's disease.

Authors:  Sandra E Leh; Michael Petrides; Antonio P Strafella
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

8.  The importance of childhood trauma and childhood life events for chronicity of depression in adults.

Authors:  Jenneke E Wiersma; Jacqueline G F M Hovens; Patricia van Oppen; Erik J Giltay; Digna J F van Schaik; Aartjan T F Beekman; Brenda W J H Penninx
Journal:  J Clin Psychiatry       Date:  2009-07       Impact factor: 4.384

9.  An fMRI study of prefrontal brain activation during multiple tasks in patients with major depressive disorder.

Authors:  Paul B Fitzgerald; Anusha Srithiran; Jessica Benitez; Zafiris Z Daskalakis; Tom J Oxley; Jayashri Kulkarni; Gary F Egan
Journal:  Hum Brain Mapp       Date:  2008-04       Impact factor: 5.038

10.  Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety.

Authors:  J M Gatt; C B Nemeroff; C Dobson-Stone; R H Paul; R A Bryant; P R Schofield; E Gordon; A H Kemp; L M Williams
Journal:  Mol Psychiatry       Date:  2009-01-20       Impact factor: 15.992

View more
  11 in total

Review 1.  Transdiagnostic impairment of cognitive control in mental illness.

Authors:  Lisa M McTeague; Madeleine S Goodkind; Amit Etkin
Journal:  J Psychiatr Res       Date:  2016-08-05       Impact factor: 4.791

Review 2.  Opioid modulation of cognitive impairment in depression.

Authors:  Moriah L Jacobson; Hildegard A Wulf; Caroline A Browne; Irwin Lucki
Journal:  Prog Brain Res       Date:  2018-09-18       Impact factor: 2.453

3.  Social supports moderate the effects of child adversity on neural correlates of threat processing.

Authors:  Nicholas F Wymbs; Catherine Orr; Matthew D Albaugh; Robert R Althoff; Kerry O'Loughlin; Hannah Holbrook; Hugh Garavan; Janitza L Montalvo-Ortiz; Stewart Mostofsky; James Hudziak; Joan Kaufman
Journal:  Child Abuse Negl       Date:  2020-02-14

4.  A shared effect of paroxetine treatment on gray matter volume in depressive patients with and without childhood maltreatment: A voxel-based morphometry study.

Authors:  Xiao-Wen Lu; Hua Guo; Jing-Rong Sun; Qiang-Li Dong; Fu-Tao Zhao; Xu-Hong Liao; Li Zhang; Yan Zhang; Wei-Hui Li; Ze-Xuan Li; Tie-Bang Liu; Yong He; Ming-Rui Xia; Ling-Jiang Li
Journal:  CNS Neurosci Ther       Date:  2018-09-12       Impact factor: 5.243

5.  History of childhood maltreatment augments dorsolateral prefrontal processing of emotional valence in PTSD.

Authors:  Gregory A Fonzo; Julia Huemer; Amit Etkin
Journal:  J Psychiatr Res       Date:  2015-12-19       Impact factor: 4.791

6.  Sex-Specific Association Between High Traumatic Stress Exposure and Social Cognitive Functioning in Youths.

Authors:  Ran Barzilay; Lauren K White; Monica E Calkins; Tyler M Moore; Jami F Young; Daniel H Wolf; Theodore D Satterthwaite; Ruben C Gur; Raquel E Gur
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2018-06-22

7.  The new field of 'precision psychiatry'.

Authors:  Brisa S Fernandes; Leanne M Williams; Johann Steiner; Marion Leboyer; André F Carvalho; Michael Berk
Journal:  BMC Med       Date:  2017-04-13       Impact factor: 8.775

Review 8.  Intrinsic Brain Network Biomarkers of Antidepressant Response: a Review.

Authors:  Katharine Dunlop; Aleksandr Talishinsky; Conor Liston
Journal:  Curr Psychiatry Rep       Date:  2019-08-13       Impact factor: 5.285

Review 9.  Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment.

Authors:  Beata R Godlewska; Catherine J Harmer
Journal:  Psychopharmacology (Berl)       Date:  2020-01-15       Impact factor: 4.530

Review 10.  Synaptic Plasticity, Metaplasticity and Depression.

Authors:  Linnea R Vose; Patric K Stanton
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.